Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. The implant sends continuous glucose sensing data to a transmitter device attached to the patient’s skin with a silicone adhesive. This transmitter then sends the data to a mobile app, where the patient can evaluate their glucose levels and take action.
Through this partnership, Senseonics and Welldoc plan to deliver a next-generation app that maintains all existing features from which patients currently benefit, alongside new features to enhance user experience and facilitate better integration with popular digital health tools.
Get the full story at our sister site, Drug Delivery Business News.
